Patents by Inventor Holly M. Horton

Holly M. Horton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20230272114
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: December 22, 2022
    Publication date: August 31, 2023
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 11566080
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 31, 2023
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20210205426
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: August 10, 2020
    Publication date: July 8, 2021
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20200332024
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 22, 2020
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20170335013
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 23, 2017
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9617348
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9540451
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: January 10, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9266966
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 23, 2016
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9221916
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: December 29, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9062117
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 23, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20150139985
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 21, 2015
    Inventors: JOHN DESJARLAIS, SEUNG Y. CHU, HOLLY M. HORTON, MATTHEW J. BERNETT
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20150093379
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventors: JOHN DESJARLAIS, SEUNG Y. CHU, HOLLY M. HORTON, MATTHEW J. BERNETT
  • Novel Compositions and Methods for Treating IgE-Mediated Disorders
    Publication number: 20130177553
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 11, 2013
    Applicant: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 8435517
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: May 7, 2013
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20110189178
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Applicant: XENCOR, INC.
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20100080814
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: September 17, 2009
    Publication date: April 1, 2010
    Applicant: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton
  • Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
    Publication number: 20030091544
    Abstract: The present invention relates to methods of treating an autoimmune disease or an inflammatory condition, and in particular multiple sclerosis, in a mammal comprising administering a therapeutically effective amount of a non-infectious, non-integrating polynucleotide construct encoding a &bgr; interferon or an active fragment or variant thereof, wherein said construct is not associated with transfection-facilitating viral particles, liposomal formulations, or charged lipids.
    Type: Application
    Filed: March 13, 2002
    Publication date: May 15, 2003
    Applicant: Vical Incorporated
    Inventors: Suezanne E. Parker, Holly M. Horton